Cargando…
KRAS G12V Mutation Detection by Droplet Digital PCR in Circulating Cell-Free DNA of Colorectal Cancer Patients
KRAS mutations are responsible for resistance to anti-epidermal growth factor receptor (EGFR) therapy in colorectal cancer patients. These mutations sometimes appear once treatment has started. Detection of KRAS mutations in circulating cell-free DNA in plasma (“liquid biopsy”) by droplet digital PC...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4848940/ https://www.ncbi.nlm.nih.gov/pubmed/27043547 http://dx.doi.org/10.3390/ijms17040484 |
_version_ | 1782429452754485248 |
---|---|
author | Olmedillas López, Susana García-Olmo, Dolores C. García-Arranz, Mariano Guadalajara, Héctor Pastor, Carlos García-Olmo, Damián |
author_facet | Olmedillas López, Susana García-Olmo, Dolores C. García-Arranz, Mariano Guadalajara, Héctor Pastor, Carlos García-Olmo, Damián |
author_sort | Olmedillas López, Susana |
collection | PubMed |
description | KRAS mutations are responsible for resistance to anti-epidermal growth factor receptor (EGFR) therapy in colorectal cancer patients. These mutations sometimes appear once treatment has started. Detection of KRAS mutations in circulating cell-free DNA in plasma (“liquid biopsy”) by droplet digital PCR (ddPCR) has emerged as a very sensitive and promising alternative to serial biopsies for disease monitoring. In this study, KRAS G12V mutation was analyzed by ddPCR in plasma DNA from 10 colorectal cancer patients and compared to six healthy donors. The percentage of KRAS G12V mutation relative to wild-type sequences in tumor-derived DNA was also determined. KRAS G12V mutation circulating in plasma was detected in 9 of 10 colorectal cancer patients whose tumors were also mutated. Colorectal cancer patients had 35.62 copies of mutated KRAS/mL plasma, whereas in healthy controls only residual copies were found (0.62 copies/mL, p = 0.0066). Interestingly, patients with metastatic disease showed a significantly higher number of mutant copies than M0 patients (126.25 versus 9.37 copies/mL, p = 0.0286). Wild-type KRAS was also significantly elevated in colorectal cancer patients compared to healthy controls (7718.8 versus 481.25 copies/mL, p = 0.0002). In conclusion, KRAS G12V mutation is detectable in plasma of colorectal cancer patients by ddPCR and could be used as a non-invasive biomarker. |
format | Online Article Text |
id | pubmed-4848940 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-48489402016-05-04 KRAS G12V Mutation Detection by Droplet Digital PCR in Circulating Cell-Free DNA of Colorectal Cancer Patients Olmedillas López, Susana García-Olmo, Dolores C. García-Arranz, Mariano Guadalajara, Héctor Pastor, Carlos García-Olmo, Damián Int J Mol Sci Article KRAS mutations are responsible for resistance to anti-epidermal growth factor receptor (EGFR) therapy in colorectal cancer patients. These mutations sometimes appear once treatment has started. Detection of KRAS mutations in circulating cell-free DNA in plasma (“liquid biopsy”) by droplet digital PCR (ddPCR) has emerged as a very sensitive and promising alternative to serial biopsies for disease monitoring. In this study, KRAS G12V mutation was analyzed by ddPCR in plasma DNA from 10 colorectal cancer patients and compared to six healthy donors. The percentage of KRAS G12V mutation relative to wild-type sequences in tumor-derived DNA was also determined. KRAS G12V mutation circulating in plasma was detected in 9 of 10 colorectal cancer patients whose tumors were also mutated. Colorectal cancer patients had 35.62 copies of mutated KRAS/mL plasma, whereas in healthy controls only residual copies were found (0.62 copies/mL, p = 0.0066). Interestingly, patients with metastatic disease showed a significantly higher number of mutant copies than M0 patients (126.25 versus 9.37 copies/mL, p = 0.0286). Wild-type KRAS was also significantly elevated in colorectal cancer patients compared to healthy controls (7718.8 versus 481.25 copies/mL, p = 0.0002). In conclusion, KRAS G12V mutation is detectable in plasma of colorectal cancer patients by ddPCR and could be used as a non-invasive biomarker. MDPI 2016-04-01 /pmc/articles/PMC4848940/ /pubmed/27043547 http://dx.doi.org/10.3390/ijms17040484 Text en © 2016 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons by Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Olmedillas López, Susana García-Olmo, Dolores C. García-Arranz, Mariano Guadalajara, Héctor Pastor, Carlos García-Olmo, Damián KRAS G12V Mutation Detection by Droplet Digital PCR in Circulating Cell-Free DNA of Colorectal Cancer Patients |
title | KRAS G12V Mutation Detection by Droplet Digital PCR in Circulating Cell-Free DNA of Colorectal Cancer Patients |
title_full | KRAS G12V Mutation Detection by Droplet Digital PCR in Circulating Cell-Free DNA of Colorectal Cancer Patients |
title_fullStr | KRAS G12V Mutation Detection by Droplet Digital PCR in Circulating Cell-Free DNA of Colorectal Cancer Patients |
title_full_unstemmed | KRAS G12V Mutation Detection by Droplet Digital PCR in Circulating Cell-Free DNA of Colorectal Cancer Patients |
title_short | KRAS G12V Mutation Detection by Droplet Digital PCR in Circulating Cell-Free DNA of Colorectal Cancer Patients |
title_sort | kras g12v mutation detection by droplet digital pcr in circulating cell-free dna of colorectal cancer patients |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4848940/ https://www.ncbi.nlm.nih.gov/pubmed/27043547 http://dx.doi.org/10.3390/ijms17040484 |
work_keys_str_mv | AT olmedillaslopezsusana krasg12vmutationdetectionbydropletdigitalpcrincirculatingcellfreednaofcolorectalcancerpatients AT garciaolmodoloresc krasg12vmutationdetectionbydropletdigitalpcrincirculatingcellfreednaofcolorectalcancerpatients AT garciaarranzmariano krasg12vmutationdetectionbydropletdigitalpcrincirculatingcellfreednaofcolorectalcancerpatients AT guadalajarahector krasg12vmutationdetectionbydropletdigitalpcrincirculatingcellfreednaofcolorectalcancerpatients AT pastorcarlos krasg12vmutationdetectionbydropletdigitalpcrincirculatingcellfreednaofcolorectalcancerpatients AT garciaolmodamian krasg12vmutationdetectionbydropletdigitalpcrincirculatingcellfreednaofcolorectalcancerpatients |